Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bethanechol versus domperidone for oral feeding intolerance in hospitalized children
IRCT20190522043672N5Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, triple-blind trial of bethanechol and domperidone in feeding intolerance (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Nutritional tolerance. Started May 2023; status: completed.
02
Drugs
bethanecholdomperidone
03
Conditions
feeding intolerance
Beyond the preview
Go deeper on IRCT20190522043672N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190522043672N5.